Hundreds of HIV doctors and researchers have called on the Trump administration to reverse its sweeping aid funding cuts, saying they are "doing catastrophic harm" to the global fight against AIDS.
Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.
Switching to long-acting ART from oral treatments was cost effective for postpartum women with HIV and improved infant outcomes, researchers said at the Conference on Retroviruses and Opportunistic ...
Human rights, key and vulnerable populations Ethiopia received PEPFAR funding for work on stigma, discrimination and enabling legal environments. As a result of the USG stop-work order, all programmes ...
Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Sex Workers, MSM, and Transgender Persons: Disruption in access to PrEP services, reduced capacity for HIV prevention services, , reduced availability of HIV counselling and testing, and disruption in ...
The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...
UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
This research on a T-cell–targeting vaccines in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of ...
An American biochemist whose research has helped scientists make inroads on treating coronavirus and HIV has won this year’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results